Clinical experience and the results of animal studies show that rapid instillation is more effective than slow instillation and it results in a better distribution of surfactant dose. Surfactants used in this manner are typically instilled directly into the trachea. Rds in a premature infant is defined as respiratory distress requiring more than 30% oxygen delivered by. Surfactant replacement therapy beyond respiratory distress syndrome in neonates article pdf available in indian pediatrics 533.
Sinkin, md, mph surfactant replacement therapy srt has a proven role in the treatment of neonatal respiratory distress syndrome and severe meconium aspiration syndrome in infants, and may have a role in the treatment of pediatric patients with ards. Minimally invasive surfactant therapy with a gastric tube is as effective as the intubation, surfactant, and extubation technique in preterm babies. Although newer delivery mechanisms and strategies are being studied, the classic surfactant administration paradigm consists of. Objective to evaluate incidence of minimally invasive surfactant therapy mist failure, identify risk factors and assess the impact of mist failure on neonatal outcome. Surfactant therapy substantially reduces mortality and respiratory morbidity for this population. Surfactant replacement therapy for neonates better safer. A sample size of 110 neonates from a population of 150 premature neonates in neonatal icu of kamc were selected. Secondary surfactant deficiency also contributes to acute respiratory morbidity in latepreterm and term neonates with meconium aspiration. Pdf surfactant replacement therapy beyond respiratory.
Late surfactant administration in very preterm neonates with. Official journal of the california perinatal association. Apr 25, 2016 surfactant replacement therapy srt has been shown to reduce mortality and air leaks in preterm neonates from highincome countries hics. Clinical report surfactantreplacementtherapyforpretermandterm. Surfactant therapy for respiratory distress syndrome. Respiratory failure secondary to surfactant deficiency is a major cause of morbidity and mortality in preterm neonates. Recommendations for neonatal surfactant therapy paediatrics. Surfactant replacement therapy srt has a proven role in the treatment of neonatal respiratory distress syndrome and severe meconium aspiration syndrome in infants, and may have a role in the treatment of pediatric patients with ards.
Beyond respiratory distress syndrome steven m donn md and jennifer dalton md introduction meconium aspiration syndrome surfactant replacement surfactant lavage bronchopulmonary dysplasia summary surfactantreplacement therapy is a lifesaving treatment for preterm infants with respiratory. Surfactant replacement therapy for rds early rescue therapy should be practiced. Secondary surfactant deficiency also contributes to acute respiratory morbidity in latepreterm and term neonates with meconium aspiration syndrome, pulmonary. Pdf incidence and outcome of surfactant therapy in premature.
Surfactant replacement therapy for preterm and term neonates with respiratory distress. Withdraw the mac catheter from the et tube as it severely reduces or occludes the et tube lumen and restricts ventilation which can lead to adverse events desaturation, bradycardia, and chest rigidity. Surfactant replacement therapy, either as a rescue treatment or a prophylactic natural surfactant therapy, reduces mortality evidence level 1a and several aspects of morbidity in babies with rds. Respiratory distress syndrome in newborn and surfactant therapy. Secondary surfactant deficiency also contributes to acute respiratory morbidity in latepreterm and term neonates with meconium aspiration syndrome, pneumonia. Surfactant dysfunction is well described in acute lung injury. This surface active material was later termed as surfactant, which is a. Surfactant therapy is the medical administration of exogenous surfactant. Pdf surfactant replacement therapy for preterm and term.
Who recommendation on surfactant replacement therapy for. According to established guidelines 64, mothers at risk of delivering babies. Surfactant therapy in respiratory distress syndrome the. Efficacy and safety of surfactant replacement therapy for preterm neonates with respiratory distress syndrome in low and middleincome countries. Guidelines for surfactant administration surfactant. Two basic strategies for surfactant replacement have emerged. Surfactant replacement therapy should be considered in. Its introduction was also associated with a 6% reduction in infant mortality in the usa. Surfactant reduced both neonatal mortality and pulmonary air leaks by about 50%.
Surfactant replacement therapy improved oxygenation in the study subjects, suggesting that surfactant may have a role in the treatment of severe mas in term and nearterm infants. Mist failure was defined as need for early mechanical ventilation title. Early administration of exogenous surfactant via the endotracheal tube to premature infants significantly reduces the severity of rds. Mist failure was defined as need for early mechanical ventilation in 1959, commented on the deficiency of a surface active material in the alveolar linings of the lungs of preterm babies with respiratory distress syndrome rds.
Surfactant in preterm infants introduction pulmonary surfactant is a complex mixture of phospholipids and proteins that serves to reduce alveolar surface tension. It has been shown in multiple randomized controlled trials that the use of exogenous surfactant in preterm infants improves oxygenation, decreases air leaks, reduces mortality due to rds, and decreases overall mortality. Surfactant creates a continuously reforming surface layer. In addition, there are various neonatal respiratory. Surfactant replacement therapy improved oxygenation in the study subjects, suggesting that surfactant may have a role in the treatment of. Surfactant replacement therapy srt has been shown to reduce mortality and air leaks in preterm neonates from highincome countries hics. Surfactant replacement therapy for preterm and term neonates. Our objective was to identify the factors which would. Surfactant administration strategies have been based on manufacturer guidelines for individual surfactants.
Background surfactant replacement therapy is an established modality of treatment in preterm neonates with respiratory distress syndrome. Exogenous surfactant therapy has become well established in newborn infants with respiratory distress. To this recommendation can be found in the who guidelines, available at. Preterm infants and surfactant effectiveness in clinical trials surfactant trials have included infants born between 23 and 34 weeks gestation andor with birth weight between 500 and 2000 g. First dose needs to be given as soon as diagnosis of rds is made. Dosing guidelines for surfactant replacement therapy in the nicu. It is formed by type ii pneumocytes from about 20 weeks of gestation. Sep 01, 2009 surfactant replacement therapy is a lifesaving treatment for preterm infants with respiratory distress syndrome, a disorder characterized by surfactant deficiency. Dec 18, 2019 the guidelines for surfactant therapy are largely based on studies done in developed coun1tries wherein the facility infrastructure, patient profile, and clinical practices are different from low and middleincome countries lmics.
Respiratory distress syndrome rds of the newborn, also known as hyaline membrane disease, is a breathing disorder of premature babies. Who recommendation on the type of surfactant for surfactant. Halliday in 1959 avery and mead demonstrated that surfactant deficiency was a key feature in the pathogenesis of respiratory distress syndrome rds. This outcome is achieved by reducing the surface tension and promoting alveolar stability during expiration. Aarc clinical practice guideline surfactant replacement. Surfactant replacement therapy for neonates better safer care.
The technique involves placement of a fine intratracheal catheter while babies keep spontaneously breathing on ncpap. Surfactant replacement therapy for neonates with respiratory. In healthy infants, the alveolithe small, airexchanging sacs of the lungsare coated by surfactant, which is a soaplike material produced in the lungs as the fetus matures in preparation for birth. Respiratory failure secondary to surfactant deficiency is a major cause of morbidity and mortality in preterm infants. Clinical practice guideline guideline coverage includes nicu.
Rds in a premature infant is defined as respiratory distress requiring more than 30%. Surfactant therapy an overview sciencedirect topics. Surfactant replacement therapy srt for preterm neonates with. Avery and mead in 1959, commented on the deficiency of a surface active material in the alveolar linings of the lungs of preterm babies with respiratory distress syndrome rds. The mean sd age at which surfactant was given was 5. Surfactant replacement therapy for preterm and term.
Fortysix infants weighing 1499 g were randomized into two groups. Improved outcome at 28 days of age for very low birth weight infants treated with a single dose of a synthetic surfactant. Minisymposium neonates surfactant therapy in the newborn c. Repletion with exogenous surfactant decreases mortality and thoracic air leaks and is a standard practice in the developed world. When a baby comes out of the womb and the lungs are not developed yet, they require administration of surfactant in order to process oxygen and survive. In addition to respiratory distress syndrome, other neonatal respiratory disorders are characterized. These morbidities include deficits in oxygenation, the incidence of pulmonary air leaks pneumothorax and pulmonary interstitial emphysema and. Etiology of surfactant inactivation or dysfunction. Surfactants generally have been administered via intratracheal instillation. Although newer delivery mechanisms and strategies are being studied, the classic surfactant administration paradigm consists of endotracheal intubation. Surfactant treatment has been shown by careful randomised trials to reduce the mortality and morbidity of very premature babies. Surfactant was the first drug developed solely for treatment of neonates.
Brian walsh discusses the use of surfactant replacement therapy in the treatment of preterm and term neonates suffering from respiratory distress syndrome rds. Bolus surfactant therapy by tracheal catheterization, another method of administering surfactant while avoiding ventilation, has been developed in german neonatal units. Surfactant replacement therapy may be considered in. Surfactant replacement therapy in neonatal respiratory. Rds in a premature infant is defined as respiratory distress requiring more than 30% oxygen delivered by positive pressure using either nasal cpap or an et tube with a chest radiograph that has. Purpose and definitions surfactant therapy is given to minimise atelectasis and reduce the work of breathing. Secondary surfactant deficiency also contributes to acute respiratory morbidity in latepreterm and term neonates with meconium aspiration syndrome, pneumoniasepsis, and perhaps. Though srt is widely practiced in developing countries, there exists variability in clinical practice. Recommendations for neonatal surfactant therapy ncbi. Exogenous surfactant therapy substantially reduces mortality and respiratory morbidity. The use of surfactant replacement therapy in neonatal pneumonia has not been. Synthetic lung surfactant drug information, professional.
This statement summarizes the evidence and gives recommendations for the use of surfactant therapy in. Neonates who received proteinfree synthetic surfactant had similar risk of overall neonatal mortality compared to natural surfactants rr 1. Guidelines for surfactant administration surfactant replacement. The surfactant is indicated in all neonates with rds.
752 1606 180 312 464 1141 1358 461 632 267 142 403 112 581 351 1369 16 1362 1407 653 1473 1496 1123 945 76 83 414 1378 1294 1093 167 1185 356 1333 777